Literature DB >> 25573529

CD44v6 promotes β-catenin and TGF-β expression, inducing aggression in ovarian cancer cells.

Jing Wang1, Ling Xiao2, Chen-Hui Luo3, Hui Zhou3, Liang Zeng3, Jingmin Zhong1, Yan Tang3, Xue-Heng Zhao3, Min Zhao3, Yi Zhang1.   

Abstract

A high expression of CD44v6 has been reported in numerous malignant cancers, including stomach, prostate, lung and colon. However, the pathological role and the regulatory mechanisms of CD44v6 have yet to be elucidated. In the present study, the expression levels of CD44v6 were shown to be significantly higher in ovarian cancer tissues, as compared with adjacent normal tissues. Furthermore, the upregulated expression levels of CD44v6 were correlated with disease recurrence and poor survival in patients. The expression of CD44v6 was knocked down in the CAOV3 ovarian cell line, by transfection of a specific small hairpin RNA. The present study showed a correlation between the aggression, viability, invasion and migration of the ovarian cancer cells, with the expression of CD44v6. In addition, the expression of CD44v6 was positively correlated with the expression levels of β‑catenin and tumor growth factor‑β, which indicates that the effects of CD44v6 on ovarian cancer cell aggression may be mediated by these two signaling pathways. In conclusion, the present study provides a novel insight into the association between CD44v6 expression and ovarian cancer. CD44v6 may provide a novel target for the prognosis and treatment of ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25573529     DOI: 10.3892/mmr.2015.3145

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  8 in total

1.  AIP1 Expression in Tumor Niche Suppresses Tumor Progression and Metastasis.

Authors:  Weidong Ji; Yonghao Li; Yun He; Mingzhu Yin; Huanjiao Jenny Zhou; Titus J Boggon; Haifeng Zhang; Wang Min
Journal:  Cancer Res       Date:  2015-07-02       Impact factor: 12.701

2.  CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling.

Authors:  Bianca N Lourenço; Nora L Springer; Daniel Ferreira; Carla Oliveira; Pedro L Granja; Claudia Fischbach
Journal:  Integr Biol (Camb)       Date:  2018-02-16       Impact factor: 2.192

3.  Alternative CD44 splicing identifies epithelial prostate cancer cells from the mesenchymal counterparts.

Authors:  James R Hernandez; John J Kim; James E Verdone; Xin Liu; Gonzalo Torga; Kenneth J Pienta; Steven M Mooney
Journal:  Med Oncol       Date:  2015-04-09       Impact factor: 3.064

4.  CD44v6: A metastasis-associated biomarker in patients with gastric cancer?: A comprehensive meta-analysis with heterogeneity analysis.

Authors:  Li Lu; Fei Huang; Zhicheng Zhao; Chuan Li; Tong Liu; Weidong Li; Weihua Fu
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

5.  Understanding the role of CD44V6 in ovarian cancer.

Authors:  Hui-Feng Zhang; Peng Hu; Sheng-Quan Fang
Journal:  Oncol Lett       Date:  2017-06-13       Impact factor: 2.967

6.  CD44v6 overexpression related to metastasis and poor prognosis of colorectal cancer: A meta-analysis.

Authors:  Ji-Lin Wang; Wen-Yu Su; Yan-Wei Lin; Hua Xiong; Ying-Xuan Chen; Jie Xu; Jing-Yuan Fang
Journal:  Oncotarget       Date:  2017-02-21

7.  LINC01605 knockdown induces apoptosis in human Tenon's capsule fibroblasts by inhibiting autophagy.

Authors:  Qifei Shang; Yanhua Yang; Hangzhu Li
Journal:  Exp Ther Med       Date:  2022-03-22       Impact factor: 2.447

8.  ILC1 drive intestinal epithelial and matrix remodelling.

Authors:  Michael D A Norman; Tracy T L Yu; Joana F Neves; Eileen Gentleman; Geraldine M Jowett; Patricia Rosell Arévalo; Dominique Hoogland; Suzette T Lust; Emily Read; Eva Hamrud; Nick J Walters; Umar Niazi; Matthew Wai Heng Chung; Daniele Marciano; Omer S Omer; Tomasz Zabinski; Davide Danovi; Graham M Lord; Jöns Hilborn; Nicholas D Evans; Cécile A Dreiss; Laurent Bozec; Oommen P Oommen; Christian D Lorenz; Ricardo M P da Silva
Journal:  Nat Mater       Date:  2020-09-07       Impact factor: 47.656

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.